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Abstract
Background: Mood disorders were found associated with fibromyalgia (FM) and clinical studies have
revealed the efficacy of antidepressant drugs in the treatment of FM. However no specific instruments
to identify manic symptoms were used.
Objectives: To assess the frequency of anxiety and mood disorders (particularly bipolar disorders
and manic symptoms) in a consecutive sample of women affected by FM using standardized diagnostic
tools and to compare the prevalence of these disorders with that observed in a sample of healthy
controls from the general population.
Methods: Cases: consecutive series of women (N = 37, mean age 50.1 ± 21.0) attending a
Rheumatology outpatient Unit at the University of Cagliari. Controls: 148 women, drawn from the
data bank of an epidemiological study matched for sex and age with controls according to a
randomisation "after blocks" method. The Italian version of the Composite International Diagnostic
Interview Simplified were carried out by physicians. Psychiatric diagnosis was formulated according to
DSM-IV criteria. The Italian version of the Mood Disorder Questionnaire (MDQ) was administered
to identify manic symptoms and bipolar disorders. Diagnosis of FM were carried out by
rheumatologist according to the criteria of American College of Rheumatology.
Results: Subjects with FM showed a higher comorbidity with Generalised Anxiety Disorder, Panic
Disorder and Major Depressive Disorder than controls. The study showed a high frequency of manic
symptoms (MDQ positive) in the sample of fibromyalgic patients (59%), approximately double that
found in the control sample (P < 0.001).
Discussion: Clinical studies have shown the efficacy of antidepressants, especially tricyclic
antidepressants, in the treatment of FM. The clinical difficulty in identifying hypomanic episodes is well
known particularly where previous and not present episodes are concerned as in depressive patients.
These data would suggest further studies on the subject are needed and more caution also in
prescribing antidepressants in a population apparently at high risk for bipolar disorders.
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Several studies, reported high frequency of mood disor-
ders in subjects affected by fibromyalgia (FM) [1,2] and
short term clinical studies have revealed the efficacy of
antidepressant drugs in the treatment of FM [3]. However,
no specific instruments to identify manic symptoms were
used in these studies. Bipolar Disorders (BD) are
renowned to be hard to distinguished by Major Depres-
sive Disorders in research studies when using "traditional"
psychiatric diagnostic tools such as interviews carried out
by lay interviewer and not by clinicians [4].
The cause of the close association with mood disorders
and the efficacy of antidepressants in FM patients is not
yet clear. Specific polymorphisms of genes codifying for
serotonin transporters and the catechol-O-methyltrans-
ferase enzyme which inactivates catecholamines, neuro-
transmitters implicated in the pathogenesis of affective
disorders, have been associated with FM [5]. It has how-
ever been acknowledged that the clinical picture of FM
often overlaps with those of the Chronic Fatigue Syn-
drome and Irritable Bowel Syndrome: response to stress is
considered to play a crucial role in the pathogenesis of
these disorders [6,7]. But the efficacy of antidepressants in
this group of disorders may be related to the analgesic
effect of these drugs rather that their antidepressant effect
and appears strongest in agents with mixed-receptor or
predominantly noradrenergic activity, rather than serot-
oninergic activity [8]
The lack of specific information as to the nature and gen-
esis of FM-associated affective disorders is clinically rele-
vant.
A hypothetical risk of bipolar disorder in fibromyalgic
patients has recently been suggested in observational
studies [9]; should this hypothesis be confirmed, particu-
lar caution would be required in the use of antidepressant
drugs. In the course of bipolar disorders, antidepressant
drugs are particularly indicated in the case of depressive
episodes whilst the use of these drugs alone (without the
concomitant use of mood stabilizers) should be avoided
due to the serious risk of manic switching and to induce
rapid cycling in the long term [10].
Objectives
The aim of this study is to assess the frequency of anxiety
and mood disorders in a consecutive sample of women
affected by FM using standardized diagnostic tools
administered by clinicians and to compare the prevalence
of these disorders with that observed in a sample of
healthy controls from the general population. The study
also aims to evaluate the presence of manic and
hypomanic symptoms among the fibromyalgic patients
by means of specific tools such as the Mood Disorder
Questionnaire [11].
A comparison of familiarity for mood disorders will be
performed between cases and healthy controls.
Methods
The sample of cases was made up of a consecutive series
of women attending the Psychiatric Consultancy Service
in the Rheumatology Department of the University of
Cagliari.
The case sample included 37 women aged 25 to 72 years,
mean age 50,1 ± 21,0 years, whilst controls were drawn
from the data bank of an epidemiological study per-
formed on the general Sardinian population [12].
The control group included 148 women and was arranged
according to a randomisation "after blocks" method: for
each case a "cell" including all control subjects of the same
sex and age (± 1 year) as the patients was set up.
Four controls were obtained at random from each cell (4
controls for each case).
Each control was contacted and reassessed (approxi-
mately 5 years after the epidemiological survey), 15
women (10.1%) refused to take part in the study or could
not be traced. All refusals were substituted by extracting a
new proband at random from the same cell as the subject
who had refused.
Clinical assessment and statistical analysis
The Italian version of the Composite International Diag-
nostic Interview Simplified [13] was used to assess the
presence of anxiety and depressive disorders and to verify
familiarity for mood disorders among both cases and con-
trols. Interviews were carried out by physicians who had
been working in the field of Psychiatry for at least two
years. Psychiatric diagnosis was formulated according to
DSM-IV criteria.
The Italian version of the Mood Disorder Questionnaire
[14] was administered to identify manic symptoms and
bipolar disorder. This is a self-administered test which
establishes fairly reliably whether an individual has man-
ifested a manic or hypomanic syndrome during his life.
The test is made up of 13 closed questions (yes/no
answers) and was elaborated bearing in mind the criteria
laid down by DSM-IV and by clinical experience.
An excellent degree of sensitivity and specificity of the
instrument has been demonstrated by the preliminary val-
idation stages of the Italian version [14] in a sample of
subjects attending the Psychiatric Unit of the UniversityPage 2 of 5
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wards.
The test may therefore prove useful in screening for type I
and II bipolar disorders in the sample studied here.
The possible presence of somatic disorders among con-
trols, indicating the absence of FM, was evaluated by
means of a questionnaire examining physical wellbeing
used previously in the epidemiological survey.
The major inclusion criteria for FM were the American
College of Rheumatology (ACR) 1990 classification crite-
ria for fibromyalgia [15]: e.g. widespread pain for at least
3 months (pain in the left side of the body, plus right side
of the body, plus pain above the waist, plus pain below
the waist, plus axial pain; axial pain includes pain in the
cervical spine, or thoracic pain, or pain in the low back or
anterior chest wall) and the presence of 11 tender points
among 18 specified sites. Pressure of 4 kg/cm (enough to
whiten the examiner's fingernail) should be applied to
each point for a few seconds. Exclusion criteria were con-
comitant rheumatic diseases. 40 healthy females (aged
27–72, mean age 47.89 + 9.76) were also studied. All FM
patients were examined by an experienced rheumatolo-
gist. The pain pressure threshold measurements of
patients with FM were performed using a mechanical
algometer. Pain threshold was defined as the amount of
pressure adequate to induce sensation of discomfort, and
the subjects were informed that the aim was not to deter-
mine pain tolerance. 18 tender points accepted by the
ACR for FM were evaluated. All the measurements and
tests were carried out by the same doctor throughout the
study.
Statistical analysis was performed by assessing the fre-
quency of anxiety and depressive disorders among both
cases and controls. The measure of association is
expressed as "Odd Ratio" (OR). Confidence intervals of
OR were calculated using the simplified method of Miet-
tinen [16]
Results
Table 1 shows the comparison of frequency in lifetime
psychiatric diagnosis between FM patients and controls
concerning Generalised Anxiety Disorder, Panic Disorder
and Major Depressive Episodes. Subjects with FM showed
an higher comorbidity with Generalized Anxiety Disor-
der, Panic Disorder and Major Depressive Disorder than
controls. 19 FM patients presented comorbidity with an
anxiety or depressive disorder (51.35%); in 9 FM patients
no psychiatric disorders were found (24.32%); 11 con-
trols presented comorbidity with both anxiety and depres-
sive disorders (7.43%, P < 0.001), no psychiatric disorders
were found in 91 controls (61.48%, P < 0.001).
The frequency of bipolar disorders was calculated using a
threshold value of 6 as this was the cut-off frequently used
in international epidemiological studies: 19 positives
(29.7%) were identified among subjects with fibromyal-
gia compared to 20 in the controls (13.5%, χ2 = 4.48, OR
= 2.7, P = 0.034). If we assume as cut-off 4 or more symp-
toms + impairment as used in Italian studies and as rec-
ommended for investigations during the validation stages
of the Italian version [14] 22 positive cases (59.4%) were
identified among subjects with fibromyalgia compared to
44 (28.0%) in the controls (χ2 = 10.1, OR = 3.5, P =
0.001).
Table 2 shows the comparison between these results and
the most recent studies carried out in different settings.
Comparison with the US community survey [17] was car-
ried out recalculating the frequencies using the lower
comparable cut-off.
A familiarity for depressive disorders of 40.54% was
found in the FM patients compared to 20.27% in the con-
trols (P < 0.001).
Discussion and conclusion
The data obtained by us confirmed, by means of a stand-
ardised international method, what had already appeared
in literature regarding the association between fibromyal-
gia and anxiety and mood disorders.
A multi-centre study carried out by Epstein et al. [2]
showed that anxiety levels seemed correlated in a signifi-
cant manner to compromised functional ability found in
patients with fibromyalgia and noted an important asso-
ciation between depression and fibromyalgia; Cohen H.
Table 1: Frequency of psychiatric disorders in patients with fibromyalgia and controls
Generalized Anxiety 
Disorder
Social Phobia Panic Disorder Major Depressive Disorder MDQ+ (4 or more symptom + impairment)
CASES 15 (40.5%) 3 (8.11%) 10 (27.1%) 23 (62.16%) 22 (59.4%)
CONTROLS 23 (15.54%) 4 (2.70%) 5 (3.38%) 20 (13.51%) 44 (28.0%)
OR 3.7 3.2 16.8 3.47
X2 9.89 1.12 28.8 10.1
P 0,002 0.289 < 0,001 < 0,001 <0.001Page 3 of 5
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fibromyalgia and post-traumatic disorders. These authors
maintain that common anxiety and depressive disorders
are associated with FM and could be independent of the
principle symptoms of rheumatic illness and that they
could however be correlated to the negative consequences
of the effects of the symptoms on quality of life and social
function.
However, the close familiarity that emerged from our
studies, confirming previous findings [19], cannot
exclude the hypothesis of a common biological vulnera-
bility [19].
The most important datum, regarding clinical implica-
tions, reported to date, is the high frequency of positive
MDQ in the sample of fibromyalgic patients. This fre-
quency is approximately double that found in the control
sample and higher than in studies carried out on the gen-
eral Italian population [20] and in an US community sur-
vey [17] the latter comparison, if we re-calculated the
prevalence assuming a comparable cut-off (> 6 symptoms
i.e. moderate – severe impairment) (see table 2). The fre-
quency of MDQ is even higher to that found in case series
of patients attending a public psychiatric service in the
same Italian town [14].
The evidence of highly frequent panic and generalised
anxiety disorders in the sample of fibromyalgic patients
confirms indirectly the hypothesis of the risk of bipolarity.
It is known that patients affected by bipolar disorders
have a high risk of anxiety disorders, even higher than that
of patients affected by major depression [21].
Recent clinical studies have shown the efficacy of anti-
depressants, especially tricyclic antidepressants, in the
treatment of FM [3]. Their use has consequently been
extended to other non psychiatric settings. The clinical dif-
ficulty in identifying hypomanic episodes is well known
particularly where previous and not present episodes are
concerned as in depressive patients [4]. These data would
suggest further studies on the subject are needed and more
caution also in prescribing antidepressants in a popula-
tion apparently at high risk for bipolar disorders.
Furthermore, it must considered that in the subjects
accepted for clinical studies on depressive disorder in FM,
psychiatric diagnosis was carried out by a psychiatrist
using proven methodologies, this can render the samples
very diverse from cases found in current rheumatological
practice, also with regards to the frequency of bipolar
depression and to the consequent risk of inducing mania
with antidepressants.
Furthermore, clinical trials on the use of anti-depressants
in FM are very short and possible negative effects (in the
order of onset of maniacal symptoms, mixed and/or
induction of rapid cycles) should be evaluated over the
medium term considering that most of the patients have
some ongoing affective disorder on entering the trials.
Considering that the efficacy obtained in clinical studies
by some psychotherapic treatments has been shown to be
virtually identical to that when using antidepressants in
FM [22,23], should our data be confirmed, then the con-
sequence would be that psychotherapic treatments of
proven efficacy in FM should be considered first choice
compared to antidepressants.
Limits
The study used healthy controls, when in most studies the
controls for FM patients are patients with Rheumatoid
Arthritis. In fact, it's obvious that anxiety/depressive
symptoms/disorders are much more common among
non-healthy than among healthy people. But this discrep-
ancy may be just due to dificulties in cope with a disease
(such as FM). Nevertheless the main result of this study is
the high frequency of MDQ positives in the sample of
fibromyalgic patients suggesting high rates of bipolar dis-
orders. This finding was never observed in other rheu-
matic disorders. Future studies need to confirm if the
association with bipolar disorders is specific for fibromy-
algia or it is common in other rheumatic disorders.
Table 2: Frequency of MDQ positiveness in recent clinical and epidemiological studies
Study Year % Positiveness Setting
Carta et al. Cagliari (Italy) 2006 59.4 (29.7*) Fibromyalgic patients
Hardoy et al. Cagliari (Italy) 2005 34.4 Psychiatric patients
Hirshfeld et al. US 2003 3.7* Community
Mangelli et al. Bologna (Italy) 2005 17.7 Community
*> 6 symptoms i.e. moderate – severe impairmentPage 4 of 5
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